Bifonazole
 | |
| Clinical data | |
|---|---|
| Trade names | Canespor, many others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| ATC code | D01AC10 (WHO) |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
60628-96-8  |
| PubChem (CID) | 2378 |
| DrugBank |
DB04794 |
| ChemSpider |
2287 |
| UNII |
QYJ305Z91O |
| KEGG |
D01775 |
| ChEBI |
CHEBI:31286  |
| ChEMBL |
CHEMBL277535 |
| Chemical and physical data | |
| Formula | C22H18N2 |
| Molar mass | 310.392 g/mol |
| 3D model (Jmol) | Interactive image |
| Chirality | Racemic mixture |
| |
| |
| (what is this?) (verify) | |
Bifonazole is an imidazole antifungal drug. Bifonazole is marketed by Bayer under the trade name Canespor in ointment form. Many other trade names exist.[1]
There are also combinations with carbamide for the treatment of onychomycosis.
Adverse effects
The most common side effect is a burning sensation at the application site. Other reactions, such as itching, eczema or skin dryness, are rare.[2]
Pharmacology
Mechanism of action
Bifonazole has dual mode of action. It inhibits fungal ergosterol biosynthesis at two points, via transformation of 24-methylendihydrolanosterol to desmethylsterol, together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs.[2][3]
Pharmacokinetics
Six hours after application, bifonazole concentrations range from 1000 µg/cm³ in the stratum corneum to 5 µg/cm³ in the papillary dermis.[2]
References
- ↑ International Drug Names: Bifonazole.
- 1 2 3 Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- ↑ Berg, D; Regel, E; Harenberg, H. E.; Plempel, M (1984). "Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole". Arzneimittel-Forschung. 34 (2): 139–46. PMID 6372801.
- Lackner, T. E.; Clissold, S. P. (1989). "Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses". Drugs. 38 (2): 204–25. doi:10.2165/00003495-198938020-00004. PMID 2670516.